Study of long COVID in Brazil
Part of Infections, Lungs & breathing clinical trials.
This study looks at how often “post-COVID-19 condition” (long COVID) happens, what factors are linked to it, and how much it affects people’s daily lives. It may help researchers better understand long COVID and who is most impacted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You live in Brazil
- You had confirmed COVID-19 (by test) after January 2022
- Your COVID symptoms started at least 90 days before you join
- You can join remote (online) study visits
- You can communicate in Portuguese and understand study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks on people who had covid-19 and still had symptoms months later. It aims to see how these long-term symptoms change over five years and what health challenges remain.
This study follows people with lasting or complex COVID-19 symptoms who are already in a specialized care program. It aims to better understand and improve recovery after COVID.
This study looks at how COVID-19 can affect health and quality of life over the long term. It may help researchers understand symptoms that can last and what changes people experience after recovery.
This study follows adults who had COVID-19 to learn how the illness can affect health over the long term. It may help researchers understand lasting symptoms and who is at higher risk, which could improve future care.
This trial studies people who had COVID-19 to understand why some develop long-term symptoms while others recover fully. It aims to find links between the immune system and brain changes using imaging.
This trial studies how your immune system responds in people with Long COVID after a past COVID-19 infection. It may help researchers understand why symptoms linger and how the body’s response could be targeted.
Hear when a new Post-Acute COVID-19 Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.